Paratek Pharmaceuticals (PRTK) – Analyst Ratings
-
H.C. Wainwright Reiterates Buy Rating, $20 on Paratek Pharmaceuticals (PRTK) on NUZYRA's Fast-Track Designation
-
H.C. Wainwright Reiterates Buy Rating on Paratek Pharmaceuticals (PRTK), Cites Impressive Preclinical Results in MAC Lung Infections
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to PRTK Stock Lookup